Elicio Therapeutics, INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
NASDAQ
Christopher Haqq, See Remarks of Elicio Therapeutics, Inc., received 64,643 shares of common stock on July 16, 2026.
NASDAQ
Peter Demuth, Chief Scientific Officer of Elicio Therapeutics, Inc., received 52,832 shares of common stock on July 16, 2026.
NASDAQ
Preetam Shah, See Remarks of Elicio Therapeutics, Inc., received 60,833 shares of common stock on July 16, 2026.
NASDAQ
Robert Connelly, CEO, President and Director and a Director of Elicio Therapeutics, Inc., received 186,944 shares of common stock on July 16, 2026.
NASDAQ
Elicio Therapeutics CEO Robert Connelly received substantial equity awards, including restricted stock units and stock options, effective February 2, 2026.
NASDAQ
Elicio Therapeutics, Inc. granted 24,000 restricted stock units and 47,900 stock options to Chief Strategy and Financial Officer Preetam Shah.
NASDAQ
Elicio Therapeutics' Chief Scientific Officer, Peter DeMuth, was granted 20,800 restricted stock units and options to purchase 41,600 shares of common stock.
NASDAQ
Elicio Therapeutics, Inc. awarded its Executive Vice President, Head of R&D and Chief Medical Officer, Christopher Haqq, 25,400 restricted stock units and 50,900 stock options.
NASDAQ
Elicio Therapeutics' Chief Scientific Officer, Peter DeMuth, exercised stock options to acquire 362 shares of common stock at $4.41 per share.
NASDAQ
Yekaterina Chudnovsky, a Director and 10% owner of Elicio Therapeutics, Inc., indirectly acquired 103,225 warrants to purchase common stock through GKCC, LLC.
NASDAQ
Yekaterina Chudnovsky, a director of Elicio Therapeutics, acquired stock options exercisable for 7,900 shares of common stock.
NASDAQ
Director Carol Ashe reports acquisition of stock options in Elicio Therapeutics.
NASDAQ
Allen Nissenson, a director of Elicio Therapeutics, acquired stock options for 7,900 shares of common stock on May 19, 2025.
NASDAQ
Jay Venkatesan, a director of Elicio Therapeutics, acquired stock options for 7,900 shares of common stock on May 19, 2025.
NASDAQ
Director Julian Adams acquired stock options for 7,900 shares of Elicio Therapeutics common stock on May 19, 2025.
NASDAQ
Director Karen Wilson reports the grant of stock options in Elicio Therapeutics, Inc.
NASDAQ
Robert Ruffolo, a director of Elicio Therapeutics, acquired stock options for 7,900 shares of common stock on May 19, 2025.
NASDAQ
Preetam Shah, Chief Strategy and Financial Officer of Elicio Therapeutics, acquired stock options for 191,624 shares of common stock on April 15, 2025.
NASDAQ
Yekaterina Chudnovsky, a director and 10% owner of Elicio Therapeutics, converted a convertible note held by GKCC, LLC into common stock on March 5, 2025.
NASDAQ
Peter DeMuth, Chief Scientific Officer of Elicio Therapeutics, acquired stock options for 44,400 shares on February 3, 2025.
NASDAQ
Christopher Haqq, Executive Vice President, Head of R&D and Chief Medical Officer of Elicio Therapeutics, acquired 44,000 stock options on February 3, 2025.
NASDAQ
Robert Connelly, CEO of Elicio Therapeutics, reports the acquisition of stock options.
NASDAQ
Jay Venkatesan, a director of Elicio Therapeutics, filed an amended Form 4 to correct a previous filing regarding the acquisition of common and pre-funded warrants.
NASDAQ
Peter DeMuth, Chief Scientific Officer of Elicio Therapeutics, exercised stock options at a price of $4.41 on December 16, 2024.
NASDAQ
Director Jay Venkatesan exercised pre-funded warrants to acquire 50,000 shares of Elicio Therapeutics common stock at a price of $0.01 per share.
NASDAQ
Karen Wilson, a director at Elicio Therapeutics, acquired 4,100 stock options on November 21, 2024.
NASDAQ
Director Julian Adams of Elicio Therapeutics acquired 4,100 stock options on November 21, 2024, which will vest on the earlier of November 21, 2025, or the next annual meeting.
NASDAQ
Director Carol Gail Ashe of Elicio Therapeutics acquired 4,100 stock options on November 21, 2024, which will vest on the earlier of November 21, 2025, or the next annual meeting.
NASDAQ
Jay Venkatesan, a director at Elicio Therapeutics, acquired 4,100 stock options on November 21, 2024.
NASDAQ
Robert Ruffolo, a director at Elicio Therapeutics, was granted stock options for 4,100 shares on November 21, 2024.